Avaleht › Müeloom › Ohio › Cleveland
Müeloom kliinilised uuringud linnas Cleveland, OH
16 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Cleveland ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
VärbamineFaas 3
- Research Site, Cleveland
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
VärbamineFaas 2
- University Hospitals Cleveland Medical Center, Cleveland
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
VärbamineFaas 2
- Cleveland Clinic, Cleveland
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
VärbamineFaas 3
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Main Campus, Cleveland
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
VärbamineFaas 3
- Cleveland Clinic, Cleveland
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1/2
- Research Site, Cleveland
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
VärbamineFaas 3
- Cleveland Clinic, Cleveland
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
VärbamineFaas 3
- MetroHealth Medical Center, Cleveland
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
VärbamineFaas 1
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
VärbamineFaas 3
- Research Site, Cleveland
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
VärbamineFaas 3
- Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
VärbamineVaatlusuuring
- University Hospitals Seidman Cancer Center, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
- Cleveland Clinic, Cleveland
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 1
- Cleveland Clinic, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
VärbamineFaas 1/2
- University Hospitals Cleveland, Cleveland
LMY-920 for Treatment of Relapsed or Refractory Myeloma
VärbamineFaas 1
- University Hospitals Seidman Cancer Center, Cleveland
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas Cleveland
- Mitteväikerakuline kopsuvähk43 uuringut
- Vähk (kõik liigid)36 uuringut
- Rinnavähk35 uuringut
- Eesnäärmevähk34 uuringut
- Südamepuudulikkus33 uuringut
- Metastaatiline vähk30 uuringut
- Munasarjavähk30 uuringut
- Kopsuvähk26 uuringut
- Käär- ja pärasoolevähk24 uuringut
- Kardiovaskulaarsed haigused22 uuringut
- Endomeetriumivähk20 uuringut
- Äge müeloidne leukeemia20 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.